Mesa Laboratories, Inc. (NASDAQ:MLAB) Holdings Lifted by Raymond James & Associates

Raymond James & Associates boosted its stake in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) by 8.4% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 80,739 shares of the medical instruments supplier's stock after buying an additional 6,283 shares during the period. Raymond James & Associates owned approximately 1.49% of Mesa Laboratories worth $7,006,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of MLAB. Price T Rowe Associates Inc. MD increased its stake in Mesa Laboratories by 6.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,873 shares of the medical instruments supplier's stock worth $316,000 after purchasing an additional 175 shares during the period. EntryPoint Capital LLC lifted its stake in Mesa Laboratories by 35.2% in the first quarter. EntryPoint Capital LLC now owns 741 shares of the medical instruments supplier's stock worth $81,000 after acquiring an additional 193 shares during the period. Quadrant Capital Group LLC lifted its stake in Mesa Laboratories by 515.6% in the fourth quarter. Quadrant Capital Group LLC now owns 277 shares of the medical instruments supplier's stock worth $29,000 after acquiring an additional 232 shares during the period. BNP Paribas Financial Markets grew its holdings in Mesa Laboratories by 4.5% during the 1st quarter. BNP Paribas Financial Markets now owns 7,565 shares of the medical instruments supplier's stock worth $830,000 after acquiring an additional 327 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co increased its position in Mesa Laboratories by 7.6% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 6,968 shares of the medical instruments supplier's stock valued at $761,000 after purchasing an additional 494 shares during the period. 90.60% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on MLAB shares. Wells Fargo & Company began coverage on shares of Mesa Laboratories in a research report on Tuesday. They issued an "underweight" rating and a $120.00 price target for the company. Evercore ISI increased their target price on Mesa Laboratories from $106.00 to $120.00 and gave the company an "outperform" rating in a research report on Tuesday, August 6th.

Mesa Laboratories Stock Down 3.6 %

Shares of MLAB stock traded down $5.13 during mid-day trading on Wednesday, hitting $135.73. 48,578 shares of the stock traded hands, compared to its average volume of 43,879. Mesa Laboratories, Inc. has a 52-week low of $82.86 and a 52-week high of $145.46. The stock has a market cap of $734.16 million, a P/E ratio of -2.99 and a beta of 0.86. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.37 and a quick ratio of 1.86. The stock's fifty day moving average is $108.93 and its two-hundred day moving average is $107.08.

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last posted its quarterly earnings data on Monday, August 5th. The medical instruments supplier reported $2.29 EPS for the quarter, topping the consensus estimate of $1.74 by $0.55. The firm had revenue of $58.17 million during the quarter, compared to analyst estimates of $55.90 million. Mesa Laboratories had a negative net margin of 117.61% and a positive return on equity of 10.10%. Equities analysts predict that Mesa Laboratories, Inc. will post 6.91 EPS for the current year.

Mesa Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 16th. Shareholders of record on Friday, August 30th will be paid a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.47%. The ex-dividend date is Friday, August 30th. Mesa Laboratories's dividend payout ratio (DPR) is presently -1.36%.

About Mesa Laboratories

Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions.